Generated by AI
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies that deliver genetic medicines to sites of disease. The company’s current programs center on stem cell-based and oncolytic virus platforms designed to transport therapeutic payloads directly into tumors while helping protect them from premature immune clearance. Its portfolio includes product candidates for cancers such as high-grade glioma and solid tumors, reflecting a focus on oncology and precision delivery methods. Calidi Biotherapeutics also works across systemic and localized treatment approaches, using proprietary cell-based technologies to support tumor targeting, immune activation, and controlled payload delivery. Headquartered in San Diego, California, Calidi Biotherapeutics plays a role in the broader biopharmaceutical market as a developer of advanced immuno-oncology and gene therapy solutions.
Website4475 Executive Drive
San Diego, CA, 92121
United States
The latest articles about CLDI.
Detailed price information for Calidi Biotherapeutics Inc (CLDI-A) from The Globe and Mail including charting and trades.
Detailed price information for Calidi Biotherapeutics Inc (CLDI-A) from The Globe and Mail including charting and trades.
Summary of Sep 23's posts. Generated by AI.
Summary of May 27's posts. Generated by AI.
SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that it has entered into a definitive stock purchase agreement with certain accredited investors and/or qualified institutional buyers for the purchase and sale of 1,025,640 shares of the Company’s common stock, in a registered direct offering, at a per share purchase price o
Summary of Jul 24's posts. Generated by AI.
Investors talking about CLDI also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.